Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Australia-based Living Cell Technologies has announced that a US patent has been issued for the company's lead product DiabeCell, currently in development for type I diabetes.
Subscribe to our email newsletter
This patent covers the use of DiabeCell in the treatment of type I diabetes, and includes the technique for preparing encapsulated neonatal porcine pancreatic islets. This is claimed to be the fourth US patent that has been issued to the company for its lead product DiabeCell.
Paul Tan, CEO of Living Cell Technologies, said: “The acceptance of the full patent by the US patent office is a significant addition to our patent portfolio and will assist in the development of insulin producing cell transplantation. We have seen positive preliminary results in human clinical trials with this technology, and this supports the fact that the commercial implications and value added by this granted patent are noteworthy.”